Michelle Werner
About Michelle Werner
Michelle C. Werner's Education and Expertise
Michelle C. Werner holds a B.A. in biology and anthropology from the University of Pennsylvania. She earned an MBA from London Business School, further enhancing her business acumen. In 2018, she completed an Executive Education program for Women on Boards at Harvard Business School, focusing on leadership and governance.
CEO Michelle C. Werner's Professional Background
Michelle C. Werner is the Chief Executive Officer and Director, bringing extensive experience in the pharmaceutical and oncology sectors. Before her current role, she served as Worldwide Franchise Head, Solid Tumors at Novartis Oncology. Her professional journey includes leadership roles at AstraZeneca, such as Global Franchise Head in Hematology and Head of US Oncology. Prior to that, she worked at Bristol Myers Squibb for 10 years, gaining expertise in sales, marketing, and market access.
Career Beginnings in Oncology: Michelle C. Werner
Michelle C. Werner began her professional career in R&D, working closely with patients at the Oncology Clinical Trials Unit at Harvard Medical School. This hands-on experience in clinical trials shaped her understanding of oncology from a patient-centric perspective and laid the groundwork for her subsequent roles in the pharmaceutical industry.
Michelle C. Werner's Involvement with Rare Disease Community
Michelle C. Werner is an active member of the rare disease community. She currently holds a Board appointment for Rare Disease Renegades, a non-profit organization. Her involvement in this area highlights her commitment to addressing the challenges faced by patients with rare diseases.
Personal Life of CEO Michelle C. Werner
Beyond her professional achievements, Michelle C. Werner is a devoted wife and mother to three children. She balances her demanding career with her role at home, reflecting her dedication to both her family and her professional responsibilities.